A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients

Pediatric Pulmonology

Volumn 46, Issue 10, 2011, Pages 987-990

  Zobell, Jeffery T ^a,b   Young, David C ^c   Waters, C Dustin ^d   Ampofo, Krow ^c   Cash, Jared ^a   Marshall, Bruce C ^e   Olson, Jared ^a   Chatfield, Barbara A ^b  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d McKay Dee Hospital Center   (United States)

^e CYSTIC FIBROSIS FOUNDATION   (United States)

Author keywords

antibiotics; Pseudomonas aeruginosa; pulmonary exacerbations

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CLAVULANATE POTASSIUM PLUS TICARCILLIN; MEROPENEM; TAZOBACTAM;

ACCREDITATION; ACUTE PULMONARY EXACERBATION; ANTIMICROBIAL THERAPY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; ELECTRONICS; HEALTH SURVEY; HUMAN; LUNG DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS PSEUDOALCALIGENES; REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; DATA COLLECTION; DISEASE PROGRESSION; DRUG UTILIZATION; HUMANS; PSEUDOMONAS;

EID: 80052961649     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21467     Document Type: Review

References (20)

1. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med 2009; 180: 802-808.
2. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
3. Gibson RL, Burns JL, Ramsey BW,. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med 2003; 168: 918-951. (Pubitemid 37267172)
4. Microbiology and Infectious Disease in Cystic Fibrosis. Cystic Fibrosis Foundation Consensus Conference. 1994; Volume V, Section I.
5. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ,. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
6. Nelson Textbook of Pediatrics 18th Edition by Kliegman, Behrman, Jenson, and Stanton; 2007, Elsevier, Inc. 1119, 1182.
7. Red Book 29th Edition; 2009 Report of the Committee on Infectious Diseases; The American Academy of Pediatrics.
8. Drug Information Handbook. Lexi-Comp, Inc. 2010.
9. Pediatric Dosage Handbook. Lexi-Comp, Inc. 2010.
10. U.S., Census Bureau 2000; Census 2000 Geographic Definitions [Online]. Available:. html#US [Accessed on September 28, 2010].
11. Reed MD, Aronoff SC, Stern RC, Yamashita TS, Myers CM, Friedhoff LT, Blumer JL,. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Pediatr Pulmonol 1986; 2: 282-286.
12. Huls CE, Prince RA, Seilheimer DK, Bosso JA,. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993; 37: 1414-1416. (Pubitemid 23202363)
13. Reed MD, Stern RC, O'Brien CA, Yamashita TS, Myers CM, Blumer JL,. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother 1985; 27: 583-588. (Pubitemid 15097664)
14. Bui KQ, Ambrose PG, Nicolau DP, Lapin CD, Nightingale CH, Quintiliani R,. Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients. Chemotherapy 2001; 47: 153-156. (Pubitemid 32304647)
15. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL,. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101-109.
16. De Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL,. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990; 47: 73-78. (Pubitemid 20041213)
17. Lietman PS,. Pharmacokinetics of antimicrobial drugs in cystic fibrosis: β-lactam antibiotics. Chest 1988; 84: 115S-119S.
18. Cystic Fibrosis Foundation Patient Registry 2009 Annual Data Report. Bethesda, MD; 2009.
19. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C, et al. Continuous versus intermittent infusions of ceftazidime for exacerbations of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
20. Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA,. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010; 9: 280-283.